Hudson Capital Management LLC grew its holdings in shares of Taro Pharmaceutical Industries Ltd. (NYSE:TARO) by 18.7% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 7,993 shares of the company’s stock after purchasing an additional 1,261 shares during the quarter. Hudson Capital Management LLC’s holdings in Taro Pharmaceutical Industries were worth $789,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also made changes to their positions in TARO. APG Asset Management N.V. boosted its stake in Taro Pharmaceutical Industries by 1.2% during the 4th quarter. APG Asset Management N.V. now owns 226,200 shares of the company’s stock worth $19,725,000 after purchasing an additional 2,700 shares during the last quarter. LMR Partners LLP acquired a new position in shares of Taro Pharmaceutical Industries during the 4th quarter valued at about $3,246,000. Parametrica Management Ltd acquired a new position in shares of Taro Pharmaceutical Industries during the 4th quarter valued at about $306,000. Highstreet Asset Management Inc. boosted its position in shares of Taro Pharmaceutical Industries by 62.0% during the 4th quarter. Highstreet Asset Management Inc. now owns 5,865 shares of the company’s stock valued at $614,000 after acquiring an additional 2,244 shares during the last quarter. Finally, Aperio Group LLC boosted its position in shares of Taro Pharmaceutical Industries by 6.4% during the 4th quarter. Aperio Group LLC now owns 55,266 shares of the company’s stock valued at $5,787,000 after acquiring an additional 3,300 shares during the last quarter. 10.67% of the stock is currently owned by institutional investors.
NYSE TARO opened at $114.90 on Friday. Taro Pharmaceutical Industries Ltd. has a 12 month low of $93.01 and a 12 month high of $128.46. The stock has a market capitalization of $4.62 billion, a price-to-earnings ratio of 18.59 and a beta of 0.62.
Taro Pharmaceutical Industries (NYSE:TARO) last posted its earnings results on Thursday, May 17th. The company reported $2.17 EPS for the quarter, beating the Zacks’ consensus estimate of $1.51 by $0.66. Taro Pharmaceutical Industries had a net margin of 31.90% and a return on equity of 11.33%. The company had revenue of $175.22 million for the quarter, compared to analysts’ expectations of $166.59 million. equities research analysts forecast that Taro Pharmaceutical Industries Ltd. will post 9.67 EPS for the current fiscal year.
Several research analysts have recently weighed in on the stock. Zacks Investment Research raised shares of Taro Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $129.00 price target on the stock in a research report on Saturday. HC Wainwright set a $130.00 price target on shares of Taro Pharmaceutical Industries and gave the company a “buy” rating in a research report on Tuesday. Finally, ValuEngine raised shares of Taro Pharmaceutical Industries from a “sell” rating to a “hold” rating in a research report on Wednesday, March 14th. Two investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $129.50.
Taro Pharmaceutical Industries Profile
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories.
Want to see what other hedge funds are holding TARO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Taro Pharmaceutical Industries Ltd. (NYSE:TARO).
Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.